The Impact of Proinflammatory Cytokines and Imiquimod on GLUT1 in HaCaT Keratinocytes – a Potential Anti-Psoriatic Therapeutic Target?
Cellular Physiology and Biochemistry · 2022
DOI: 10.33594/000000615 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cellular Physiology and Biochemistry, 2022. Verfasst von Sebastian Makuch und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Experimental Pathology, Wroclaw Medical University, 50-368 Wroclaw, Poland, sebastian.mk21@gmail.com. Hauptthemen laut MEDLINE: Cytokines, Psoriasis. Die Arbeit wurde bisher 4-mal zitiert (Crossref). Gefördert von: National Science Centre.
Abstract (Originalsprache)
Background/Aims: Glucose metabolism has been proven as an essential process for proliferating keratinocytes, which highlights the importance of glucose transporter-1 (GLUT1) not only in the onset of psoriasis but also in the progression and severity of this inflammation-driven disease. In this study, we attempted to find a connection between proinflammatory cytokines (IL-6, IL-17, IL-23, IL-36, TNF-α), a skin inflammation inducing agent – imiquimod (IMQ) and GLUT1 expression.
Methods
Human keratinocyte HaCaT cell line was incubated with exogenous cytokines: IL-6, IL-17A, IL-23, IL-36, TNF-α at a final concentration of 100 ng/ml, or with 1 µM of IMQ, for 48 h. Following the stimulation, glucose uptake and GLUT1 expression were evaluated. The activity of GLUT1 was measured in the presence of a selective GLUT1 inhibitor, BAY-876. The expression of GLUT1 was examined by immunofluorescence and quantified by qPCR, Western blotting and densitometry.
Results
The results from qPCR analysis showed that the administration of exogenous IL-6, IL-17, IL-23 and IL-36 to HaCaT cells resulted in upregulation of GLUT1-encoding SLC2A1 gene, while TNF-α had no significant effect. The same results were confirmed by immunofluorescence analysis, as the fluorescent intensity of GLUT1 was elevated following cytokine and IMQ stimulation. Western blot and densitometry showed that all examined cytokines, as well as IMQ, increased GLUT1 expression. HaCaT cells displayed an improved intracellular 2-deoxy-D-glucose (2-DG) uptake and GLUT1 activity after stimulation by exogenous cytokines and IMQ. The highest uptake of 2-DG was observed after IL-23 stimulation (1.93x) and the lowest after TNF-α stimulation (1.07x). BAY-876 inhibited the 2-DG uptake compared to control.
Conclusion
Our findings suggest that cytokines and IMQ may play a key role in regulating GLUT1 expression in HaCaT cells. We believe that GLUT1 overexpression could potentially be utilized in the targeted treatment of psoriasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical and Experimental Pathology, Wroclaw Medical University, 50-368 Wroclaw, Poland, sebastian.mk21@gmail.com.
- Department of Clinical and Experimental Pathology, Wroclaw Medical University, 50-368 Wroclaw, Poland.
- Faculty of Biotechnology, University of Wroclaw, Wroclaw, Poland.
- Bioimaging LaboratoryŁukasiewiczResearch Network - PORT Polish Center for Technology Development, Wroclaw, Poland.
Förderung
- National Science Centre
Zitieren
APA
Makuch, S., Kupczyk, P., Makarec, A., Chodaczek, G., Ziółkowski, P., & Woźniak, M. (2022). The Impact of Proinflammatory Cytokines and Imiquimod on GLUT1 in HaCaT Keratinocytes – a Potential Anti-Psoriatic Therapeutic Target?. Cellular Physiology and Biochemistry. https://doi.org/10.33594/000000615
Vancouver
Makuch S, Kupczyk P, Makarec A, Chodaczek G, Ziółkowski P, Woźniak M. The Impact of Proinflammatory Cytokines and Imiquimod on GLUT1 in HaCaT Keratinocytes – a Potential Anti-Psoriatic Therapeutic Target?. Cellular Physiology and Biochemistry. 2022. doi:10.33594/000000615
BibTeX
@article{Makuch2022,
author = {Makuch, Sebastian and Kupczyk, Piotr and Makarec, Alicja and Chodaczek, Grzegorz and Ziółkowski, Piotr and Woźniak, Marta},
title = {The Impact of Proinflammatory Cytokines and Imiquimod on GLUT1 in HaCaT Keratinocytes – a Potential Anti-Psoriatic Therapeutic Target?},
journal = {Cellular Physiology and Biochemistry},
year = {2022},
doi = {10.33594/000000615}
}
EUVIMED